Evidence map›Paper›PMID 35431797›Full record

ArticleFrontiers in molecular neuroscience2022

Preventing Phosphorylation of the GABA

Thuy N Vien, Michael A Ackley, James J Doherty, Stephen J Moss, Paul A Davies

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Transcription of GABATranslational psychiatry · 2025
    Article
  3. Neurosteroids: a lifelong impact on brain health.Frontiers in behavioral neuroscience · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Neurosteroid enantiomers as potentially novel neurotherapeutics.Neuroscience and biobehavioral reviews · 2023
    Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Thuy N VienDepartment of Neuroscience, Tufts University School of Medicine, Boston, MA, United States.
Michael A AckleyResearch and Non-clinical Development, Sage Therapeutics, Inc., Cambridge, MA, United States.
James J DohertyResearch and Non-clinical Development, Sage Therapeutics, Inc., Cambridge, MA, United States.
Stephen J MossDepartment of Neuroscience, Tufts University School of Medicine, Boston, MA, United States.
Paul A DaviesDepartment of Neuroscience, Tufts University School of Medicine, Boston, MA, United States.
Tufts University · USSage Therapeutics (United States) · US

Funding

Constructing inhibitory synapsesR01NS051195 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI MOSS, STEPHEN J · 2006 to 2014
$3.2M
Novel actions of neurosteroids on GABA (A) receptor traffickingR01MH097446 · NIMH · TUFTS UNIVERSITY BOSTON · PI DAVIES, PAUL ANDREW, MOSS, STEPHEN J · 2013 to 2017
$2.1M
Novel actions of neurosteroids on GABA (A) receptor traffickingR01NS108378 · NINDS · TUFTS UNIVERSITY BOSTON · PI DAVIES, PAUL ANDREW, MOSS, STEPHEN J · 2018 to 2022
$2.0M
Deficits in KCC2 activity and the pathophysiology of Status EpilepticusR01NS087662 · NINDS · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2014 to 2018
$2.0M
The role of ubiquitination in regulating GABA(A) receptor functional expressionR01NS056359 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI MOSS, STEPHEN J · 2007 to 2010
$1.4M
Determining the effects of human KCC2 mutations on neuronal excitabilityR21NS111338 · NINDS · TUFTS UNIVERSITY BOSTON · PI DAVIES, PAUL ANDREW · 2019 to 2020
$454k
Impaired KCC2 function underlies pharmacoresistant seizuresR21NS080064 · NINDS · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2013 to 2014
$452k
Sensory Hypersensitivity in Fragile X Syndrome Due to Deficits in Tonic Inhibition Reversed by Neuroactive SteroidsR21NS111064 · NINDS · TUFTS UNIVERSITY BOSTON · PI DAVIES, PAUL ANDREW · 2020 to 2021
$450k
NIMH NIH HHS R01 MH097446NINDS NIH HHS R01 NS051195NINDS NIH HHS R01 NS056359NINDS NIH HHS R01 NS087662NINDS NIH HHS R01 NS108378NINDS NIH HHS R21 NS080064NINDS NIH HHS R21 NS111064NINDS NIH HHS R21 NS111338
6 · The paper itself

Abstract

Neuroactive steroids (NASs) have potent anxiolytic, anticonvulsant, sedative, and hypnotic actions, that reflect in part their efficacy as GABA

Indexed as

anxietydrug-resistant seizuresGABAergic inhibitionloss of consciousnessneurosteroids

Identifiers

PMID35431797
PMCPMC9009507
OpenAlexW4220711268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.